文献速递心外重症与机械循环支持瓣膜外科

连续流左心室辅助装置植入时同期二尖瓣手术:INTERMACS数据库分析

Concomitant mitral valve procedures in patients undergoing implantation of continuous-flow left ventricular assist devices: An INTERMACS database analysis.
PubMed 文献 · J Heart Lung Transplant · 2017-10-10

基于INTERMACS数据库2008年4月至2014年3月4930例连续流LVAD合并中重度二尖瓣反流患者,比较二尖瓣修复(252例)、置换(11例)与未手术(4667例)的结局。同期二尖瓣手术未增加总体生存获益,但可减少再入院并改善部分患者生活质量。

要点

  • 同期二尖瓣手术未影响早期或晚期生存。
  • 二尖瓣手术患者术后1年生活质量评分更优且再入院更少。
  • 术前肺动脉血管阻力及收缩压较高的患者更可能接受二尖瓣手术。

核心结论

  • 同期二尖瓣手术总体上不增加生存获益。
  • 同期二尖瓣手术可减少再入院并改善部分患者生活质量。

研究设计与样本

  • 回顾性队列分析INTERMACS数据库2008年4月至2014年3月连续流LVAD合并中重度二尖瓣反流患者共4930例。
  • 比较二尖瓣修复252例、二尖瓣置换11例与未行二尖瓣手术4667例的结局。
  • 采用分层寿命表及风险函数多变量方法分析生存影响,并评估术后功能容量与生活质量。

主要发现

  • 二尖瓣手术组术前肺动脉血管阻力为3.6 ± 2.9 Wood单位,高于未手术组的2.9 ± 2.6 Wood单位(p = 0.0006)。
  • 二尖瓣手术组术前肺动脉收缩压为55.1 ± 13.8 mm Hg,高于未手术组的51.5 ± 14.0 mm Hg(p = 0.0003)。
  • 二尖瓣修复组2年生存率为76%,二尖瓣置换组为57%,未手术组为71%(p = 0.15)。
  • 多变量分析显示二尖瓣修复或置换均未影响早期或晚期生存。
  • 术后1年视觉模拟评分生活质量二尖瓣手术组为79.00 ± 1.73,优于未手术组的74.45 ± 0.51(p = 0.03),且二尖瓣手术组再入院更少(p < 0.0001)。

临床怎么用

  • 对连续流LVAD合并中重度二尖瓣反流患者,同期二尖瓣手术不应以延长生存为目的。
  • 在部分患者中可考虑同期二尖瓣手术以减少再入院并改善生活质量。

局限性

  • 二尖瓣置换组样本量仅11例,结果解释需谨慎。
  • 为注册数据库回顾性分析,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of existing mitral valve (MV) disease in patients undergoing left ventricular assist device (LVAD) implantation remains controversial. METHODS: Among continuous-flow LVAD patients with moderate to severe mitral regurgitation entered into the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database between April 2008 and March 2014 (n = 4,930), outcomes were compared between patients who underwent MV repair (MVr, n = 252), MV replacement (MVR, n = 11) and no MV procedure (no MVP, n = 4,667). Impact on survival was analyzed by stratified actuarial and hazard function multivariable methodology. Post-operative functional capacity and quality of life were assessed. RESULTS: Patients who underwent MVPs had higher pre-operative pulmonary vascular resistance (3.6 ± 2.9 vs 2.9 ± 2.6 Wood units; p = 0.0006) and higher pulmonary artery systolic pressures (55.1 ± 13.8 vs 51.5 ± 14.0 mm Hg; p = 0.0003). Two-year survival was 76% for patients with concomitant MVr, 57% for those with MVR and 71% for those with no MVP (p = 0.15). By multivariable analysis, neither MVr nor MVR affected early or late survival. Although improvements in post-operative functional status as evaluated by 6-minute walk distances were comparable across groups, visual analog score assessments of quality of life suggested a benefit of concomitant MVPs at 1-year post-implant (79.00 ± 1.73 vs 74.45 ± 0.51; p = 0.03), with fewer re-admissions observed for MVP patients (p < 0.0001). CONCLUSIONS: Concomitant MVPs are not associated with increased survival overall. However, MVPs are associated with benefits in terms of reduced hospital re-admission and improved quality of life in select patients.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Robertson JO, Naftel DC, Myers SL, et al. Concomitant mitral valve procedures in patients undergoing implantation of continuous-flow left ventricular assist devices: An INTERMACS database analysis. J Heart Lung Transplant. 2017. PMID: 29150326. doi:10.1016/j.healun.2017.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。